438 related articles for article (PubMed ID: 12436444)
41. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
42. Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
Shelley W; Quirt I; Bodurtha A; Iscoe N; Russell J; Paterson A; Young V
Cancer Treat Rep; 1985 Sep; 69(9):941-4. PubMed ID: 2992784
[TBL] [Abstract][Full Text] [Related]
43. Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Berger TG; Dieckmann D; Efferth T; Schultz ES; Funk JO; Baur A; Schuler G
Oncol Rep; 2005 Dec; 14(6):1599-603. PubMed ID: 16273263
[TBL] [Abstract][Full Text] [Related]
44. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
45. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Cui CL; Chi ZH; Yuan XQ; Lian HY; Si L; Guo J
Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619
[TBL] [Abstract][Full Text] [Related]
46. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
47. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
Agarwala SS; Ferri W; Gooding W; Kirkwood JM
Cancer; 1999 May; 85(9):1979-84. PubMed ID: 10223239
[TBL] [Abstract][Full Text] [Related]
48. Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Treat Rep; 1984 Oct; 68(10):1211-4. PubMed ID: 6525593
[TBL] [Abstract][Full Text] [Related]
49. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
[TBL] [Abstract][Full Text] [Related]
50. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
51. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Muhonen T; Turunen JP; Hahka-Kemppinen M; Pyrhönen S
J Clin Oncol; 1996 May; 14(5):1690-6. PubMed ID: 8622089
[TBL] [Abstract][Full Text] [Related]
52. A prognostic model and staging for metastatic uveal melanoma.
Eskelin S; Pyrhönen S; Hahka-Kemppinen M; Tuomaala S; Kivelä T
Cancer; 2003 Jan; 97(2):465-75. PubMed ID: 12518371
[TBL] [Abstract][Full Text] [Related]
53. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients.
Pons F; Plana M; Caminal JM; Pera J; Fernandes I; Perez J; Garcia-Del-Muro X; Marcoval J; Penin R; Fabra A; Piulats JM
Melanoma Res; 2011 Jun; 21(3):217-22. PubMed ID: 21467954
[TBL] [Abstract][Full Text] [Related]
54. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
[TBL] [Abstract][Full Text] [Related]
55. Variates of survival in metastatic uveal melanoma.
Rietschel P; Panageas KS; Hanlon C; Patel A; Abramson DH; Chapman PB
J Clin Oncol; 2005 Nov; 23(31):8076-80. PubMed ID: 16258106
[TBL] [Abstract][Full Text] [Related]
56. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E
Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083
[TBL] [Abstract][Full Text] [Related]
57. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis.
Vuoristo MS; Vihinen P; Skyttä T; Tyynelä K; Kellokumpu-Lehtinen P
Anticancer Res; 2009 May; 29(5):1755-9. PubMed ID: 19443399
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
59. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
[TBL] [Abstract][Full Text] [Related]
60. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
